Gene Editing Race Between Editas and Vertex, CRISPR Heats Up

Friday, Editas Medicine unveiled early data from the RUBY and EdiTHAL trials, demonstrating the potential of its gene editor EDIT-301 in sickle cell disease and transfusion-dependent beta thalassemia.